Cingulate Inc., a biopharmaceutical company, develops pharmaceutical products using delivery platform technology for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety in the United States. The company’s lead product candidate is CTx-1301 (dexmethylphenidate), which is in Phase 3 clinical trials. It also develops CTx-2103 (buspirone) that is in a formulation stage for the treatment of anxiety and mental health disorders; and plans to initiate the clinical plan for CTx-1302 (dextroamphetamine) to treat ADHD in children, adolescents, and adults. Cingulate Inc. was founded in 2012 and is headquartered in Kansas City, Kansas.
Metrics to compare | CING | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipCINGPeersSector | |
|---|---|---|---|---|
P/E Ratio | −1.3x | −1.5x | −0.6x | |
PEG Ratio | −0.02 | −0.04 | 0.00 | |
Price/Book | 7.8x | 1.7x | 2.6x | |
Price / LTM Sales | - | 2.3x | 3.2x | |
Upside (Analyst Target) | - | 268.8% | 41.8% | |
Fair Value Upside | Unlock | 28.6% | 5.1% | Unlock |